Fulgent Genetics (NASDAQ:FLGT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Fulgent Genetics from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·5d ago
More News
Fulgent Genetics (NASDAQ:FLGT) Hits New 12-Month High - Still a Buy?
Fulgent Genetics (NASDAQ:FLGT) Reaches New 52-Week High - What's Next...
MarketBeat·6d ago
Connor Clark & Lunn Investment Management Ltd. Increases Stake in Fulgent Genetics, Inc. $FLGT
Connor Clark & Lunn Investment Management Ltd. increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 22.2% in the second quarter, according to its most recent 13F filing with...
Piper Sandler increased their target price on shares of Fulgent Genetics from $21.00 to $30.00 and gave the stock a "neutral" rating in a research note on Tuesday...
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.22...
MarketBeat·11d ago
Fulgent Genetics (NASDAQ:FLGT) Sets New 12-Month High on Earnings Beat
Fulgent Genetics (NASDAQ:FLGT) Hits New 52-Week High on Better-Than-Expected Earnings...
MarketBeat·12d ago
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·13d ago
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +158.33% and +3.47%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
Fulgent Reports Third Quarter 2025 Financial Results
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·13d ago
Evolent Health (EVH) Misses Q3 Earnings Estimates
Evolent Health (EVH) delivered earnings and revenue surprises of -50.00% and +2.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?